Journal of pharmacy practice最新文献

Optimizing Healthcare: Implementation of a Pharmacist-To-Pharmacist Transitions of Care Pilot Program. 优化医疗保健：从药剂师到药剂师护理过渡试点项目的实施。

IF 1

Journal of pharmacy practice Pub Date : 2025-08-01 Epub Date: 2024-12-19 DOI: 10.1177/08971900241309460

Jacqueline McDonnell, Karli Combs, Randi Dockery

{"title":"Optimizing Healthcare: Implementation of a Pharmacist-To-Pharmacist Transitions of Care Pilot Program.","authors":"Jacqueline McDonnell, Karli Combs, Randi Dockery","doi":"10.1177/08971900241309460","DOIUrl":"10.1177/08971900241309460","url":null,"abstract":"Background: Transitions of care (TOC) is defined as the movement of patients between healthcare practitioners, settings and home. Ineffective TOC can lead to hospital readmissions, increased costs, and patient dissatisfaction. Pharmacists have a unique opportunity to ensure that continuity of care, in regard to medication optimization and education, is continued throughout the transition between settings. With both inpatient and ambulatory pharmacists supporting smooth discharge for hospitalized patients, an opportunity was identified to implement a pharmacist-to-pharmacist TOC program at Ascension Genesys Hospital (AGH). Objective: Implement a pharmacist-to-pharmacist TOC program at AGH. Methods: This was a single-center pilot program in which a pharmacist-to-pharmacist TOC program was implemented at AGH between January 1st and April 30th, 2024. Patients were included if they were 18 years of age and older, managed by the family medicine (FM) team, and had at least 5 medications at discharge. The FM and ambulatory pharmacists provided recommendations and all medication related problems (MRPs) and interventions were documented. Descriptive analysis was conducted. Results: A total of 25 hospitalized patients and 10 follow-up patients were included. A total of 44 inpatient MRPs and 41 outpatient MRPs were recorded. The most common inpatient MRP was antibiotic stewardship. The most common clinic MRP was medication access barrier. Conclusion: Implementation of the pilot program occurred and results were reported. These results demonstrate the importance of pharmacist involvement in TOC.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"397-402"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Pharmacist Involvement in Emergency Response. 药师参与应急响应的评价。

IF 1

Journal of pharmacy practice Pub Date : 2025-08-01 Epub Date: 2024-12-22 DOI: 10.1177/08971900241310308

Melissa A Jeghers, Christine Ji, Kelly Newman, Natalie Leung, Russel J Roberts

{"title":"Evaluation of Pharmacist Involvement in Emergency Response.","authors":"Melissa A Jeghers, Christine Ji, Kelly Newman, Natalie Leung, Russel J Roberts","doi":"10.1177/08971900241310308","DOIUrl":"10.1177/08971900241310308","url":null,"abstract":"Purpose: Emergency response teams are designed to promptly deliver care to hospitalized patients experiencing acute decompensation events. Pharmacists are an integrated part of emergency response teams and their presence at emergency response events has been shown to improve adherence to institutional and advanced cardiac life support (ACLS) guidelines. This study assesses the impact of pharmacist involvement at emergency responses and time clinical pharmacists dedicate to emergency response. Methods: A single-center, retrospective chart review assessed inpatient and ambulatory emergency responses for patients 18 and older from August 2021 through January 2022. Emergency response event-specific information was assessed using intervention documentations in the hospital electronic health record (EHR). The amount of time dedicated to emergency response by pharmacists was then converted to full-time equivalents (FTE). Results: Of the 296 emergency response documentations assessed, 242 responses were included in analysis. The primary outcome of time pharmacists dedicate to emergency responses over a six-month period was found to be 9480 minutes (158 hours). The average amount of time spent at each response was 40.7 minutes (SD 27.4 minutes), ranging from 5-210 minutes. Conclusion: The total time spent by clinical pharmacists at emergency responses within a six-month period was equivalent to approximately 26% of an FTE. Due to inability of pharmacists to document all emergency responses, this may be under-represented. More than 70% of emergency responses required 6-10 medications be prepared by pharmacists. Pharmacists made interventions 47% of the time, indicating that pharmacists play an integral role as members of emergency response teams.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"403-409"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of Urinary Tract Infections in Male Veterans With Diabetes Prescribed Sodium-Glucose Cotransporter-2 Inhibitors Versus Sulfonylureas Across the Veterans Health Administration. 退伍军人健康管理局处方钠-葡萄糖转运体-2 抑制剂与磺脲类药物的男性退伍军人糖尿病患者尿路感染风险。

IF 1

Journal of pharmacy practice Pub Date : 2025-08-01 Epub Date: 2024-10-21 DOI: 10.1177/08971900241292692

Alyson Mathis, Matthew Lane, Jennifer Meyer Reid

{"title":"Risk of Urinary Tract Infections in Male Veterans With Diabetes Prescribed Sodium-Glucose Cotransporter-2 Inhibitors Versus Sulfonylureas Across the Veterans Health Administration.","authors":"Alyson Mathis, Matthew Lane, Jennifer Meyer Reid","doi":"10.1177/08971900241292692","DOIUrl":"10.1177/08971900241292692","url":null,"abstract":"Background: Due to their mechanism of action, sodium-glucose cotransporter-2 inhibitors (SGLT2is) carry a presumed increased risk of urinary tract infection (UTI) which is reflected in current prescribing data. As SGLT2i prescribing trends increase, some retrospective studies confirm an increased risk of UTI while conflicting studies find no increased risk of UTI associated with this therapy. Objectives: This study aims to compare the odds of developing a UTI in male Veterans with type 2 diabetes mellitus (T2DM) on metformin taking a SGLT2i vs a sulfonylurea (SU) within the Veterans Health Administration (VHA). Methods: This retrospective cohort study identified male Veterans with T2DM on metformin with a new fill of SGLT2i or SU between January 1, 2020 to December 31, 2022. Patients were then assessed for UTI diagnosis. An adjusted odds ratio (AOR) was calculated. Results: The SGLT2i cohort had 5.2% of patients diagnosed with outpatient UTI and 1.6% of patients diagnosed with inpatient UTI. The SU cohort had 5.3% of patients diagnosed with outpatient UTI and 1.3% of patients diagnosed with inpatient UTI. A logistic regression analysis resulted in a decreased odds of diagnosis of outpatient UTI in the SGLT2i cohort vs the SU cohort ([AOR] = 0.91, 95% CI [0.86 - 0.96], P-value = < 0.001), and no difference in the diagnosis of inpatient UTI ([AOR] = 1.06, 95% CI [0.96 - 1.18], P-value = 0.234). Conclusion: This retrospective study of national VHA data adds to growing literature which finds no excessive risk of UTI associated with SGLT2i therapies.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"377-381"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Pharmacist-led Telehealth Medicare Annual Wellness Visits to Satisfy Quality Metrics and USPSTF Recommendations After Implementation of a Post-Visit Follow-Up Protocol. 评估药剂师主导的远程健康医疗保险年度健康访视在实施访视后随访协议后是否符合质量指标和 USPSTF 建议。

IF 1

Journal of pharmacy practice Pub Date : 2025-08-01 Epub Date: 2024-10-30 DOI: 10.1177/08971900241296638

Jessica W Skelley, Christopher J Rogers, English Gonzalez, Subin Kim, Adriane L York, Hannah Duncan, Fayth Morris

{"title":"Evaluation of Pharmacist-led Telehealth Medicare Annual Wellness Visits to Satisfy Quality Metrics and USPSTF Recommendations After Implementation of a Post-Visit Follow-Up Protocol.","authors":"Jessica W Skelley, Christopher J Rogers, English Gonzalez, Subin Kim, Adriane L York, Hannah Duncan, Fayth Morris","doi":"10.1177/08971900241296638","DOIUrl":"10.1177/08971900241296638","url":null,"abstract":"Background: A Medicare Annual Wellness Visit (MAWV) serves Medicare patients by identifying and addressing gaps in preventive services and health screenings, often aligning with outpatient practice quality metrics. Objective: Evaluate an existing pharmacist-led MAWV telehealth service, determine the baseline quality metric satisfaction rate of telehealth MAWVs, and assess for improvement after implementing a post-MAWV follow-up protocol at a suburban, lower-income primary care clinic. Methods: This IRB-exempt, single-center retrospective chart review utilized the electronic health record at Christ Health Center, Birmingham, AL. From August 2020 through May 2022, 288 charts were assessed between 2 retrospective chart reviews that included patients 18 years or older with Medicare insurance and the ability to conduct a telehealth MAWV. The first chart review assessed metric and recommendation satisfaction within 12 months of the visit. The second chart review was performed after follow-up protocol implementation to assess for additional improvement within 3 months of the visit. Results: The percentage of MAWV recommendations completed groups after implementing a follow-up protocol. For the first chart review, 57.1% of the assessed Health Resources and Services Administration (HRSA), Uniform Data System (UDS) quality metrics, and Centers for Medicare and Medicaid Services (CMS)-required MAWV components were satisfied from the first chart review compared to 53.3% of satisfied quality metrics post-protocol implementation in spite of a substantially shorter follow-up timeframe. Conclusion: Telehealth MAWVs improve preventive care and quality metric satisfaction for Medicare patients. Post-visit follow-up protocols enhance satisfaction rates. Pharmacist-led MAWVs foster interprofessional collaboration and comprehensive patient care.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"364-369"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

D-Penicillamine Induced Myelotoxicity: A Unique Case. d -青霉胺诱导骨髓毒性：一个独特的案例。

IF 1

Journal of pharmacy practice Pub Date : 2025-08-01 Epub Date: 2024-12-11 DOI: 10.1177/08971900241308626

Aliya Abdulla, Aryan Rezvani, Christopher Nelsen, Mariah I Sigala

{"title":"D-Penicillamine Induced Myelotoxicity: A Unique Case.","authors":"Aliya Abdulla, Aryan Rezvani, Christopher Nelsen, Mariah I Sigala","doi":"10.1177/08971900241308626","DOIUrl":"10.1177/08971900241308626","url":null,"abstract":"Purpose: A case of D-penicillamine-related myelotoxicity in a patient with Wilson's disease is reported. Summary: There is a paucity of literature regarding D-penicillamine (DPA) induced myelotoxicity in the setting of Wilson's disease (WD). A 22-year-old male presented with a 1-week history of bleeding gums and dizziness. Four months prior, he had been diagnosed with Wilson's disease and started on a regimen of DPA. His blood counts demonstrated profound pancytopenia. Due to concern for suspected drug-induced myelotoxicity, DPA was discontinued. Parvovirus B19, Epstein-Barr virus, cytomegalovirus, and varicella zoster virus polymerase chain reaction studies were negative and there was no evidence of hematological malignancy. Bone marrow biopsy demonstrated hypocellularity and trilineage hypoplasia with corresponding aspirate flow cytometry confirming the absence of acute leukemia. The patient was started on subcutaneous granulocyte-colony stimulating factor, provided transfusion support with packed red blood cells and platelets. Despite these measures, his blood count failed to recover, and he was discharged on eltrombopag 150 mg daily with plans for outpatient transfusion support. DPA was permanently discontinued, and he was prescribed trientine 750 mg daily. Unfortunately, his myelotoxicity remained consistent, requiring regular transfusions. He is currently undergoing evaluation for bone marrow transplant. Conclusion: DPA-induced myelotoxicity is a rare clinical entity. Our case demonstrates a unique clinical presentation of this phenomenon. Guidelines to mitigate the risk of and treat this toxicity remain to be determined.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"414-418"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacist Impact in a Post Neuro Intensive Care Virtual Clinic (PREVAIL). 药剂师对后神经重症监护虚拟诊所的影响（占上风）。

IF 1

Journal of pharmacy practice Pub Date : 2025-08-01 Epub Date: 2024-12-13 DOI: 10.1177/08971900241308624

Grace M Conroy, Danielle M Marut, Joao A Gomes, Sarah Street, Julie Idoine, Christine Ahrens

{"title":"Pharmacist Impact in a Post Neuro Intensive Care Virtual Clinic (PREVAIL).","authors":"Grace M Conroy, Danielle M Marut, Joao A Gomes, Sarah Street, Julie Idoine, Christine Ahrens","doi":"10.1177/08971900241308624","DOIUrl":"10.1177/08971900241308624","url":null,"abstract":"Background: Traditional Post-Intensive Care Recovery Clinics (PIRCs) often exclude neurocritical care patients. In 2020, a multidisciplinary team started Post Neuro Intensive Care Virtual Clinic (PREVAIL) that uses telemedicine to provide consultative care for patients with a primary neurologic injury who are at risk for post-intensive care syndrome. During clinic, critical care pharmacists perform medication reconciliations and provide drug therapy recommendations. Objectives: The objective of this observational review is to describe the pharmacists' interventions and role in a novel PIRC. Methods: A retrospective, observational review was conducted for patients who were seen in PREVAIL from December 2020 to January 2022. The pharmacist completed a medication reconciliation and provided drug therapy recommendations. Results: Amongst fifty-two PREVAIL patients, the most common neurologic diagnosis was intracerebral hemorrhage, seizures, and acute ischemic stroke. All patients were mechanically ventilated during their ICU stay, with a median ICU length of stay of 17 days [IQR 10-26]. After medication reconciliation, 93% of patients required adjustments to their medication list. After patient examination, 89% of patients required a drug therapy recommendation, with a median of three interventions per patient. Various medication classes were intervened on, most frequently antipsychotics, anti-seizure medications, antihypertensives, anticoagulants, neuromodulators, and antidepressants. Conclusion: This is the first study to evaluate pharmacist contributions at a consultative telemedicine PIRC that focuses on providing care for patients with a primary neurologic injury. PREVAIL pharmacists have a crucial role in the multidisciplinary team. Future research is required to determine the pharmacist's impact on clinical outcomes.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"390-396"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fournier's Gangrene and Sodium-Glucose Cotransporter 2 Inhibitor Use: A Report of Two Cases. 福尼尔坏疽与钠-葡萄糖共转运体 2 抑制剂的使用：两个病例的报告。

IF 1

Journal of pharmacy practice Pub Date : 2025-08-01 Epub Date: 2024-11-20 DOI: 10.1177/08971900241302881

Zane Elfessi, Elizabeth Portnoy, Harry Karydes, Sarah Zavala

引用次数: 0

A Pre-post Intervention Study Examining the Impact of a Novel Process on Administration Time for Emergent 23.4% Hypertonic Sodium Chloride Boluses. 信re：一项干预前后研究，研究一种新工艺对紧急23.4%高渗氯化钠丸给药时间的影响。

IF 1

Journal of pharmacy practice Pub Date : 2025-08-01 Epub Date: 2024-12-20 DOI: 10.1177/08971900241310993

Alexis DelBalso, Elizabeth A Feldman, Mikaela Young, Jennifer Lapp, Christopher D Miller, William Darko, Robert W Seabury

引用次数: 0

Thrombotic Safety of Angiotensin II for Distributive Shock in the Cardiothoracic Intensive Care Unit. 血管紧张素 II 治疗心胸重症监护病房分布性休克的血栓安全性。

IF 1

Journal of pharmacy practice Pub Date : 2025-08-01 Epub Date: 2024-09-26 DOI: 10.1177/08971900241287614

Christine M Cunningham, Anna E Pawlowski, Sarah B Schaidle

{"title":"Thrombotic Safety of Angiotensin II for Distributive Shock in the Cardiothoracic Intensive Care Unit.","authors":"Christine M Cunningham, Anna E Pawlowski, Sarah B Schaidle","doi":"10.1177/08971900241287614","DOIUrl":"10.1177/08971900241287614","url":null,"abstract":"Background: Angiotensin II (ATII) has been shown in the literature to increase the risk of thrombosis. Little data exists in patients with mechanical circulatory support (MCS) due to exclusion from landmark trials. Objective: Evaluate the thrombotic risk of ATII in patients in the cardiothoracic intensive care unit (CTICU) with distributive shock. Methods: Retrospective study including adult patients admitted to the CTICU with temporary MCS. This study evaluated patients ≥18 years old on temporary MCS in the CTICU between September 1st, 2018 and August 30th, 2022. Patients that received ATII were compared to a control group for the outcome of an index thrombotic event. The outcomes were compared using the Fischer's exact or chi-squared test. Results: A total of 75 patients primarily admitted for cardiac surgery were included, of which 41 (54.7%) received ATII. The rates of overall thrombosis were higher in the ATII group compared to the control, though the outcome was not statistically significant (41.5% vs 20.6%; P = 0.05). Individual thrombotic components of the composite outcome were not statistically significant between groups. Conclusion: Numerically higher rates of thrombosis were seen in patients on MCS that received ATII, though the outcome was not statistically significant. This retrospective study provides a single-center, real-world safety perspective on the use of ATII in MCS.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"370-376"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142348906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence of Thrombocytopenia With Different Continuous Renal Replacement Systems and Modalities in a Cardiac Intensive Care Unit. 心脏重症监护病房中不同连续性肾脏替代系统和模式下血小板减少症的发病率。

IF 1

Journal of pharmacy practice Pub Date : 2025-08-01 Epub Date: 2024-11-21 DOI: 10.1177/08971900241302388

Jessica C Brumit, Ryan A Caputo, Sheila M Chucta, Rachel M Smith, Samantha Warren, Kevin T Kissling

{"title":"Incidence of Thrombocytopenia With Different Continuous Renal Replacement Systems and Modalities in a Cardiac Intensive Care Unit.","authors":"Jessica C Brumit, Ryan A Caputo, Sheila M Chucta, Rachel M Smith, Samantha Warren, Kevin T Kissling","doi":"10.1177/08971900241302388","DOIUrl":"10.1177/08971900241302388","url":null,"abstract":"Background: Thrombocytopenia is due to multifactorial causes in critically ill patients. One etiology is continuous renal replacement therapy (CRRT); however, it is unknown if different modalities impact the incidence. Objectives: To compare the incidence of thrombocytopenia with the NxStage CRRT system using continuous venovenous hemodialysis (CVVHD) compared to the Prismaflex system using continuous venovenous hemodiafiltration (CVVHDF). Methods: This was a retrospective cohort study at a large academic medical center in the United States. Individuals aged 18 or older admitted to the cardiovascular ICU between June 1, 2016 and September 30, 2022, and received CRRT for at least 48 hours were identified. Results: One hundred and forty-seven patients met inclusion criteria. Sixty-one patients received CVVHD with the NxStage system, while 86 received CVVHDF with the Prismaflex system. Thrombocytopenia occurred in 57.4% of patients treated with NxStage vs 19.8% treated with Prismaflex (OR 5.46; 95% confidence interval [CI], 2.62-11.39). These results were consistent in an adjusted model (OR 5.57; 95% CI, 2.34-13.28). There was no difference in the time to thrombocytopenia between groups. Patients treated with the NxStage system had lower platelet nadirs, more heparin-induced thrombocytopenia testing, more direct thrombin inhibitor use, and more blood transfusions. Conclusions: A greater incidence of thrombocytopenia occurred in cardiovascular ICU patients treated with CVVHD using the NxStage system vs CVVHDF with the Prismaflex system.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"382-389"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0